Your browser doesn't support javascript.
Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).
Wild, Jim M; Porter, Joanna C; Molyneaux, Philip L; George, Peter M; Stewart, Iain; Allen, Richard James; Aul, Raminder; Baillie, John Kenneth; Barratt, Shaney L; Beirne, Paul; Bianchi, Stephen M; Blaikley, John F; Brooke, Jonathan; Chaudhuri, Nazia; Collier, Guilhem; Denneny, Emma K; Docherty, Annemarie; Fabbri, Laura; Gibbons, Michael A; Gleeson, Fergus V; Gooptu, Bibek; Hall, Ian P; Hanley, Neil A; Heightman, Melissa; Hillman, Toby E; Johnson, Simon R; Jones, Mark G; Khan, Fasihul; Lawson, Rod; Mehta, Puja; Mitchell, Jane A; Platé, Manuela; Poinasamy, Krisnah; Quint, Jennifer K; Rivera-Ortega, Pilar; Semple, Malcolm; Simpson, A John; Smith, Djf; Spears, Mark; Spencer, LIsa G; Stanel, Stefan C; Thickett, David R; Thompson, A A Roger; Walsh, Simon Lf; Weatherley, Nicholas D; Weeks, Mark Everard; Wootton, Dan G; Brightling, Chris E; Chambers, Rachel C; Ho, Ling-Pei.
  • Wild JM; Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Porter JC; Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK.
  • Molyneaux PL; Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
  • George PM; Department of Respiratory Medicine, University College London, London, UK.
  • Stewart I; National Heart and Lung Institute, Imperial College London, London, UK.
  • Allen RJ; Department of Interstitial Lung Disease, Royal Brompton and Harefield Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • Aul R; National Heart and Lung Institute, Imperial College London, London, UK.
  • Baillie JK; Department of Interstitial Lung Disease, Royal Brompton and Harefield Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • Barratt SL; National Heart and Lung Institute, Imperial College London, London, UK.
  • Beirne P; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Bianchi SM; Respiratory Medicine, St George's Hospital NHS Foundation Trust, London, UK.
  • Blaikley JF; Roslin Institute, University of Edinburgh, Midlothian, UK.
  • Brooke J; Bristol Interstitial Lung Diseases Service, North Bristol NHS Trust, Bristol, UK.
  • Chaudhuri N; Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Collier G; Academic Department of Respiratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Denneny EK; Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Docherty A; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Fabbri L; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Gibbons MA; NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Gleeson FV; School of Medicine, University of Nottingham, Nottingham, UK.
  • Gooptu B; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Hall IP; Respiratory Department, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
  • Hanley NA; Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
  • Heightman M; Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK.
  • Hillman TE; Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
  • Johnson SR; Department of Respiratory Medicine, University College London, London, UK.
  • Jones MG; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Khan F; National Heart and Lung Institute, Imperial College London, London, UK.
  • Lawson R; Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Mehta P; College of Medicine and Health, University of Exeter, Exeter, UK.
  • Mitchell JA; Department of Oncology, University of Oxford, Oxford, UK.
  • Platé M; Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.
  • Poinasamy K; Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Quint JK; NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Rivera-Ortega P; School of Medicine, University of Nottingham, Nottingham, UK.
  • Semple M; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Simpson AJ; Wythenshaw Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Smith D; Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
  • Spears M; Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
  • Spencer LG; NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Stanel SC; School of Medicine, University of Nottingham, Nottingham, UK.
  • Thickett DR; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Thompson AAR; Southampton NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
  • Walsh SL; NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Weatherley ND; School of Medicine, University of Nottingham, Nottingham, UK.
  • Weeks ME; Academic Department of Respiratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Wootton DG; Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK.
  • Brightling CE; School of Life & Medical Sciences, UCL, London, UK.
  • Chambers RC; National Heart and Lung Institute, Imperial College London, London, UK.
  • Ho LP; Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK.
BMJ Open Respir Res ; 8(1)2021 09.
Article in English | MEDLINE | ID: covidwho-1438096
ABSTRACT

INTRODUCTION:

The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). METHODS AND

ANALYSIS:

The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. ETHICS AND DISSEMINATION All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.

CONCLUSION:

This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Diseases, Interstitial / COVID-19 Type of study: Observational study / Risk factors Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Year: 2021 Document Type: Article Affiliation country: Bmjresp-2021-001049

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Diseases, Interstitial / COVID-19 Type of study: Observational study / Risk factors Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Year: 2021 Document Type: Article Affiliation country: Bmjresp-2021-001049